CPRX insider trading
NasdaqCM HealthcareCATALYST PHARMACEUTICALS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About CATALYST PHARMACEUTICALS, INC.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Company website: catalystpharma.com
CPRX insider activity at a glance
FilingIQ has scored 605 insider transactions for CPRX since Jan 13, 2015. The most recent filing in our index is dated Feb 17, 2026.
Across the full history, 41 open-market purchases
and 142 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CPRX insider trades is 63.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest CPRX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CPRX?
- FilingIQ tracks 605 Form 4 insider transactions for CPRX (CATALYST PHARMACEUTICALS, INC.), covering filings from Jan 13, 2015 onwards. 3 of those were filed in the last 90 days.
- Are CPRX insiders net buyers or net sellers?
- Across the full Form 4 history for CPRX, 41 transactions (7%) were open-market purchases and 142 (23%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CPRX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CPRX in?
- CATALYST PHARMACEUTICALS, INC. (CPRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.95B.
Methodology & sources
Every CPRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.